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Abstract
To assess the effect of taurine on lipopolysaccharide (LPS)-induced lung inflammation, oxidative stress and apopto-
sis, female Golden Syrian hamsters were intratracheally instilled with bacterial LPS (0.02 mg in phosphate buffered
saline (PBS) pH 7.4), before or after a 3-day intraperitoneal treatment with a single dose of taurine (50 mg/kg/day
in PBS pH 7.4), and bronchoalveolar lavage fluid (BALF) and lung tissue samples were collected at 24 hr after the
last treatment. In comparison to BALF samples from animals receiving only PBS pH 7.4, and serving as controls,
those of LPS-stimulated animals exhibited a higher count of both total leukocytes and neutrophils and increased
expression of tumor necrosis factor receptor 1. In comparison to lungs from control animals, those from LPS-trea-
ted animals showed increased cellular apoptosis, lipid peroxidation, decreased glutathione levels, altered activities
of antioxidant enzymes (catalase, glutathione peroxidase, superoxide dismutase) and focal inflammation confined
to the parenchyma. A treatment with taurine was found to significantly attenuate all these alterations, with the
protection being, in all instances, greater when given before rather than after LPS. The present results suggest that
taurine is endowed with antiinflammatory and antioxidant properties that are protective in the lung against the
deleterious actions of Gram negative bacterial endotoxin.
Background
Acute lung injury (ALI) is a characteristic sequel to
infection by Gram negative bacteria and an important
cause of morbidity and mortality in humans [1]. A com-
mon causative factor of ALI is lipopolysaccharide (LPS),
an endotoxin present in the bacterial outer membrane
[2]. Typical manifestations of ALI are alveolar and air-
way inflammatory response [3,4], the presence of inflam-
matory cells and proteinaceous fluid in air spaces [5,6],
increased microvascular permeability due to endothelial
barrier disruption [7,8], bronchoalveolar cell death [9],
and cellular changes suggestive of lung inflammation
and/or injury [10]. One major contributory factor to the
pathogenesis of ALI is the release of reactive oxygen
species (ROS) and reactive nitrogen species (RNS), pro-
teolytic enzymes, lipid mediators and proinflammatory
cytokines principally from neutrophils and alveolar and
interstitial macrophages [9]. The ensuing overwhelming
oxidative and nitrosative stresses [10,11], in turn, cause
direct damage to DNA [9], apoptosis [12], deplete
reduced glutathione (GSH) stores [13-15], promote lipid
peroxidation (LPO)[16,17], protein nitration and protein
activity alteration [18,19], inactivate antioxidant and
antiproteinase enzymes [9], and activate transcriptional
factors mediating the expression of proinflammatory
genes in phagocytic cells and in endothelial and epithe-
lial lung cells [9,20-22].
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of ALI is supported by the results of studies in experi-
mental animal models of ALI demonstrating that low
molecular weight antioxidant compounds possessing a
wide range of structural features and biological activities
are able to decrease the severity of the inflammatory
process by reducing the migration of macrophages,
monocytes and neutrophils into the lung [23] and the
production of ROS and RNS by these cells [24,25]. One
of the compounds that has demonstrated protective
actions in the lung against inflammation by LPS and
other exogenous agents is taurine (TAU), a nonprotein
amino acid with a ubiquitous distribution and a high
concentration in human tissues. As an antioxidant, TAU
is rather unique since it is able to attenuate LPO and
the loss of intracellular antioxidant defenses under con-
ditions of oxidative stress in spite of lacking a readily
oxidizable functionality [26] and has the ability to selec-
tively scavenge free radicals generated during ALI
[27,28]. For example, the addition of this compound to
cultured pneumocytes was found to reduce the LPS-
induced generation of ROS and the activation of mito-
gen-activated protein kinases and Bax [29]; and the
pretreatment of rats with 5% TAU in the drinking water
resulted in a lower number of inflammatory leukocytes
infiltrating the lung and in attenuation of the focal
bronchiolar hyperplasia that developed from a short
contact with ozone [30]. Moreover, an earlier study
from this laboratory determined that a 3-day treatment
of hamsters with TAU was able to reduce the number
of proinflammatory leukocytes, the expression of tumor
necrosis factor receptor 1 (TNFR1) on macrophages, the
activation of caspase-3 activity and accompanying apop-
tosis, LPO and the decreases in GSH and activities of
antioxidant enzymes in bronchoalveolar lavage fluid
(BALF) samples as a result of a challenge with LPS [31].
On the basis of these results, the present study was
undertaken in hamsters with the specific purpose of
determining: (a) the effects of TAU on the inflamma-
tion, oxidative stress and apoptosis that develops in lung
tissue as a result of an exposure to LPS, (b) the role of
the order of administration of TAU relative to that of
LPS on the magnitude of the effects demonstrated by
TAU, and (c) the extent to which the findings for lung
tissue samples correlate with those gathered for markers
of inflammation in BALF samples.
Methods
Materials and chemicals
All the chemicals, reagents and assay kits used in the
study were purchased from commercial sources in the
USA. H2O2 (30% w/w), LPS (serotype: O26:B6 obtained
from American Type Culture Collection no. 12795; with
short chain-length approximating that of mutant rough
s t r a i nL P S ) ,P B S ,G S H ,T A U ,T C A ,S S A ,T E Pa n dT B A
were from Sigma-Aldrich, St. Louis, MO; 0.1 N and 6 N
HCl were from Mallinckrodt Baker, Inc., Phillipsburg,
NJ; and metaphosphoric acid was from Aldrich Chemi-
cal Co., Inc., Milwaukee, WI.
Animals
Female Golden Syrian hamsters (5-6 weeks old, 100±15
g in weight, 6 per group) were purchased from Harlan,
Indianapolis, IN, USA. The animals were housed in a
temperature-controlled room (21±1°C) with a 12 hr
light-12 hr dark cycle; and had free access to a standard
hamster chow and filtered tap water for at least 7 days.
The study received the approval of the Institutional Ani-
m a lC a r ea n dU s eC o m m i t t e eo fS t .J o h n ’sU n i v e r s i t y ,
and the animals were cared in accordance with the
guidelines established by the United States Department
of Agriculture.
Treatments with LPS and TAU
To determine the effects of a pretreatment with taurine
on LPS-induced lung injury, hamsters were treated with
TAU (as a solution in phosphate buffered saline (PBS)
pH 7.4, 50 mg/kg/0.5 ml/day) by the intraperitoneal (i.
p.) route for 3 days, followed successively by an i.p. dose
of pentobarbital sodium (90 mg/kg/0.4 ml) to induce
anesthesia, and an intratracheal (i.t.) instillation of LPS
(0.2 ml of 0.1 mg/ml in PBS pH 7.4) on day 4. Controls
were treated with: (a) i.p. PBS pH 7.4 for 3 days fol-
lowed by i.t. LPS on day 4 (positive control), and (b)
only i.t. PBS pH 7.4 on day 4 (negative control). To
determine the effects of a posttreatment with TAU on
LPS-induced lung injury, the hamsters received LPS (0.2
ml of 0.1 mg/ml in PBS pH 7.4) by i.t. instillation on
day 1, followed by TAU (as a solution in phosphate buf-
fered saline (PBS) pH 7.4, 50 mg/kg/0.5 ml/day) by i.p.
route for 3 days. Control animals were treated with (a)
i.t. LPS on day 1 followed by i.p. PBS pH 7.4 on days 2
to 4 (positive control), and (b) only with i.t. PBS pH 7.4
(negative control). All i.t. instillations were carried out
using a 1-ml syringe fitted with a 27-gauge needle. Fol-
lowing an i.t. delivery, the incision was closed with
metal clips.
Collection of lung and BALF samples
On day 5, 24 h after a LPS instillation or a TAU treat-
ment, the animals were sacrificed using a high dose of
pentobarbital sodium (240 mg/kg/0.7 ml, i.p.), and
BALF samples were collected by rinsing the bronchoal-
veolar surface with PBS pH 7.4, and bringing the
volume of the pooled washings to 10 ml with addi-
tional PBS pH 7.4. Immediately thereafter, the lungs
were surgically removed, washed without delay with
ice-cold physiologic saline, patted dry with filter paper,
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in an assay.
Preparation of lung homogenates
Following their removal, the lung samples were rinsed
immediately with physiological saline, patted dry with
filter paper, weighed, and perfused with ice-cold phy-
siologic saline. A portion of lung sample was mixed
with PBS pH 7.4 in a 1:30 (w/v) ratio and made into a
fine homogenate with a hand held tissue homogenizer
(Tissue-Tearor®, BioSpec Products, Inc., Bartlesville,
OK) while keeping the mixture cold with the help of
an ice bath. After a short sonication, the suspension
was centrifuged at 14,000 rpm for 30 min, and the
supernatant used for the assays of MDA, GSH, CAT,
SOD and GPx.
Assay of MDA
The concentration of MDA in the lung was measured as
TBARS using the method of Buege and Aust [32]. An
aliquot of lung homogenate was mixed with a reagent
containing 15% TCA (w/v)-0.375% TBA (w/v)-0.25 N
HCl, and the mixture heated at 90
oCf o r1h r .A f t e r
allowing the mixture to cool to room temperature, and
a brief centrifugation step to remove insolubles, the
absorbance of the clear supernatant was read on a spec-
trophotometer at 535 nm. The concentration of MDA
was derived from a standard curve prepared from serial
dilutions of a 3.2 µM stock solution of TEP that were
treated in identical manner as the lung homogenate
samples. The concentration of MDA was expressed as
nmol/mg of protein.
Assay of GSH
The concentration of GSH in the lung homogenate was
measured following its reaction with DTNB according
to Ellman [33]. An aliquot of lung homogenate was
mixed with 5% metaphosphoric acid, the mixture centri-
fuged at 2000 x g for 5 min, and an aliquot of the clear
supernatant was mixed with 1.9 ml of 0.1 M phosphate
buffer pH 8.0 and 20 µl of 0.02 M DTNB in 0.1 M
phosphate buffer pH 8.0, and the absorbance of the
resulting product read at 412 nm on a spectrophot-
ometer. The concentration of GSH in the sample was
derived by reference to a calibration curve of GSH pre-
pared from serial dilutions of a 240 µM GSH stock solu-
tion that were treated in identical manner as the lung
homogenate samples. The result was reported as μmol/
mg of protein.
Assay of CAT activity
The activity of CAT was measured spectrophotometri-
cally as described by Aebi [34]. An aliquot of lung
homogenate was mixed with 10 times its volume of PBS
pH 7.4 and of 30 mM H2O2 in a spectrophotometric
quartz cuvette, and the absorbance of the reaction mix-
ture read without delay at 240 nm twice, immediately
after mixing and 1 min later. The activity of CAT, in U/
min/mg of protein, was calculated from the equation
[ΔOD￿Vc￿df/0.071￿Vs], where ΔOD is the difference
between the first and second absorbance readings; Vc is
the volume of the spectrophotometric cuvette in ml; Vs
is the volume of sample taken in ml; df is the dilution
factor; and 0.071 is the molar extinction coefficient of
H2O2.
Assay of GPx activity
The activity of GPx was measured indirectly by a
coupled reaction with glutathione reductase using the
spectrophotometric method of Gϋnzler and Flohé [35].
The reaction mixture contained an aliquot of lung
homogenate, glutathione reductase solution (54 U/ml),
10 mM GSH, and 15 mM b-NADPH in PBS pH 8.0.
A f t e rs t a n d i n ga tr o o mt e m p e rature, the reaction mix-
ture was mixed with 3 mM H2O2, and the change in
absorbance of the reaction mixture at 340 nm was mea-
sured for 1 min. The results are expressed in U/min/mg
of lung.
Assay of SOD activity
This enzyme activity was determined based on the inhi-
bitory action of SOD on the reduction of NBT by super-
oxide anion generated by a xanthine-xanthine oxidase
system and the conditions described by Ukeda et al.
[36]. For this purpose, an aliquot of lung homogenate
was mixed with 15% bovine serum albumin in PBS pH
8.0, 3 mM xanthine, 3 mM EDTA, 0.75 mM NBT, and
56 U/ml of xanthine oxidase. After allowing the reaction
mixture to stand at room temperature for 30 min, its
absorbance was read on a spectrophotometer at
560 nm. The enzyme activity was expressed as U/min/
mg of lung.
Histological studies
Following euthanasia of the animals with a high dose of
pentobarbital (240 mg/kg/0.7 ml, i.p.), the lungs were
fixed in situ with 10% neutral-buffered formalin for
about 2 hr at a pressure of 20 mm of water. The lungs,
along with the attached heart, were surgically removed
through a vertical incision along the thorax, and fixed in
10% neutral-buffered formalin for an additional 48 hr.
After excising any extrapulmonary structures with the
help of a scalpel, the lungs were cut into pieces of a size
suitable for histological processing, put though a stan-
dard embedding procedure in paraffin, sectioned on a
microtome, and stained with H & E. The sections where
then examined for evidence of inflammation with the
help of a light microscope.
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T h ep r e s e n c eo fl u n gi n j u r yi nt h et i s s u es e c t i o n sw a s
graded using the scale described by Szarka et al. [37].
The following scoring values were used: 0 = no reaction
in the alveolar walls, 1 = diffuse reaction in the alveolar
walls but without thickening of the interstitium, 2 = dif-
fuse presence of inflammatory cells in the alveolar walls
with a slight thickening of the interstitium, 3 = moder-
ate interstitial thickening accompanied by inflammatory
cell infiltrates, and 4 = interstitial thickening involving
more than one-half of the microscopic field. Results
were expressed as the average of the values from
50 microscopic fields.
Immunocytochemistry of TNFR1
Cytocentrifuged lung preparations were fixed with etha-
nol and permeated with an alcohol-acetic acid (2:1) mix-
ture. Endogenous peroxidase activity was quenched with
0.3% H2O2 and nonspecific binding was blocked with
goat serum (Vector Laboratories, Inc., Burlingame, CA).
After an incubation with anti-mouse TNFR1 polyclonal
antibody (Stressgen, Victoria, BC, Canada) at room tem-
perature for 30 min, and a rinsing with PBS pH 7.4, the
sample was successively incubated with biotinylated goat
anti-rabbit antibody or rabbit anti-rat antibody (Stress-
gen, Victoria, BC, Canada) at room temperature for 1
hr, and with ABC reagent (Vector Laboratories, Inc.,
Burlingame, VT) for 1 hr, prior to staining with 3,3’-dia-
minobenzidine substrate in the dark, and counterstain-
ing with methyl green. The slides were examined under
a light microscope at 400x magnification for the pre-
sence of macrophages stained in brown. For compara-
tive purposes, a negative control sample that had not
been incubated with TNFR1 primary antiserum was also
examined. The results were expressed as the number of
macrophages staining for TNFR1 in a group of 200 cells
counted in the same section. The number of macro-
phages staining for TNFR1 was reported as a percentage
of the total number of macrophages examined.
TUNEL staining for apoptosis
Lung tissue sections were digested with 20 μg/ml of
proteinase K (Sigma-Aldrich, St. Louis, MO) at room
temperature, washed with distilled water, and treated
with 0.3% H2O2 in PBS pH 7.4 to quench endogenous
peroxidase. After incubation with TdT enzyme (Chemi-
con International, Temecula, CA) at 37°C for 1 hr, the
samples were exposed to anti-digoxigenin conjugate
(Chemicon International, Temecula, CA) at room tem-
perature for 30 min. The samples were stained with
DAB peroxidase substrate (Vector Laboratories, Inc.,
Burlingame, VT), counterstained with methyl green, and
examined under a microscope. Twenty-five high-power
(HPF, 400x magnification) microscopic fields were
examined, and the results were expressed as the mean
number of TUNEL-positive cells per HPF.
Statistical analysis
The experimental results are expressed as mean ± stan-
dard error of the mean (S.E.M.) for n = 6. A significant
difference between control and treatment groups was
determined by Student’s t-test followed by one-way ana-
lysis of variance (ANOVA) and Newman-Keuls multi-
ple-range test. A P value ≤0.05 was taken as an
indication of a statistically significant difference.
Results
Effects of LPS and TAU-LPS on indices of lung oxidative
stress
Evidence of the occurrence of oxidative stress in the
lung as a result of an acute exposure to LPS was
i n f e r r e df r o mt h el e v e l so fM D A( a sT B A R S )a n dG S H
and from the activities of the antioxidant enzymes CAT,
GPx and SOD in lung homogenates. As shown in Figure
1, LPS stimulated LPO in lung tissue since it markedly
and significantly increased the formation of MDA (by
>100%, P<0.001 vs. control). The administration of TAU
for 3 days, either before or after LPS, resulted, in both
instances, in a significant reduction (by 46%, P<0.01 and
31%, P<0.05, respectively) in MDA formation induced
by LPS.
The results presented in Figure 2 indicate that, in
comparison to control values, LPS was able to reduce
the lung GSH to a significant extent (by ≥20%, P<0.05).
However, in the presence of TAU, diverging results
were obtained depending on the timing of TAU admin-
istration. While a pretreatment with this amino acid vir-
tually abolished the effect of LPS on lung GSH (only 6%
Figure 1 TAU attenuated LPS-induced formation of MDA in the
lung when given before or after LPS. Each bar represents the
mean ± S.E.M. for n = 6. *P<0.05 and ***P<0.001 vs. control;
+P<0.05
and
++P<0.01 vs. LPS.
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effect.
From the results summarized in Figures 3,4,5, it is evi-
dent that LPS exerted contrasting effects on the activ-
ities of the major antioxidant enzymes. On the one
hand, it lowered the mean activity values of both CAT
(by ~15%, P<0.05) (Figure 3) and SOD (by 27%, P<0.05)
(Figure 4) and elevated that of GPX (by ~98%, P<0.001)
(Figure 4) in comparison to the respective control
values. Regardless of its order of administration relative
to that of LPS, TAU was able to counteract these altera-
tions throughout. Thus, in the case of CAT the activities
were 75% and ~46% greater than control when given
along with LPS as a pretreatment and posttreatment,
respectively (both at P<0.001 vs. LPS). Likewise, TAU
lowered the increase in SOD activity induced by LPS by
about the same extent when given before (31% reduc-
tion) or after (34% reduction) LPS (both at P<0.01 vs.
LPS). In contrast, while TAU attenuated the elevation in
GPx activity caused by LPS, it was somewhat more
effective when given as a posttreatment (by ~49%) than
as a pretreatment (by 43%) to LPS (both at P<0.01 vs.
LPS) (Figure 5).
Effects of LPS and TAU-LPS on total leukocyte, neutrophil
and total neutrophil counts in BALF
As shown in Figure 6, an acute exposure to LPS led to a
profound increase in the total number of leukocytes
infiltrating the lung (by 12.5-fold, P<0.001) relative to
the number observed in control samples. From the
results presented in Figure 7, it is apparent that the
administration of TAU, either before or after LPS, led to
a small reduction in the number of neutrophils that
entered the lung as a result of an exposure to LPS (by
Figure 2 TAU prevented the LPS-induced depletion of lung
GSH when given before, but not after, LPS. Each bar represents
the mean ± S.E.M. for n = 6.
+P<0.05 vs. control;
+P<0.05 vs. LPS.
Figure 3 TAU attenuated the LPS-induced decrease in lung
CAT activity when given before or after LPS. Each bar represents
the mean ± S.E.M. for n = 6. ***P<0.001 vs. control;
+++P<0.001 vs.
LPS.
Figure 4 TAU attenuated the LPS-induced increase in lung GPx
activity when given before or after LPS. Each bar represents the
mean ± S.E.M. for n = 6. ***P<0.001 vs. control;
++P<0.01 vs. LPS.
Figure 5 TAU attenuated the LPS-induced decrease in lung SOD
activity when given before or after LPS. Each bar represents the
mean ± S.E.M. for n = 6. *P<0.05 vs. control;
++P<0.01 vs. LPS.
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Page 5 of 1315%, P<0.05, and 11%, respectively). Moreover, as shown
i nF i g u r e s8a n d9 ,i ti se v i d e n tt h a tat r e a t m e n tw i t h
TAU resulted in a significant attenuation of the enhan-
cing action of LPS on the total number of lung neutro-
phils, with a pretreatment providing a greater effect
(85% decrease at P<0.001 vs. LPS) than a post-treatment
(53% decrease at P<0.01 vs. LPS).
Effects of LPS and TAU-LPS on the expression of TNFR1
on BALF macrophages
An acute exposure to LPS led to a marked increase in
the expression of TNFR1 by BALF macrophages (by
~47-fold, P<0.001 vs. control). This change was signifi-
cantly attenuated by a 3-day treatment with TAU, with
the attenuation being greater when TAU was given
ahead rather than after LPS (reductions equal to 59%
and 39% respectively, P<0.01 for both vs. LPS alone)
(Figures 10 and 11).
Effects of LPS and TAU-LPS on apoptosis of lung cells
A 3-day treatment with TAU, either before or after one
with LPS, resulted in a significant decrease in the
number of alveolar cells that had entered apoptosis as a
result of an exposure to LPS (Figures 12 and 13). Based
on the results of a TUNEL assay, it was determined that
a pretreatment with TAU was more effective in curtail-
ing apoptosis (0.4 labeled cells per HPF, P<0.001) than a
posttreatment (0.5 labeled cells per HPF, P<0.01) when
compared to the number of apoptotic cells seen with
LPS alone (0.8 labeled cells per HPF, P<0.001 vs. con-
trol). Because of the limitations imposed by the proce-
dure used to stain the alveolar cells, only those cells
occupying the septa were counted.
Effects of LPS and TAU-LPS on the inflammatory index
and on lung histology
The inflammatory index was used to quantitatively
assess the extent of lung inflammation as a result of an
acute exposure to LPS. The results presented in Figure
1 4s u g g e s tt h a tt h ei n c r e a s ei nt h ev a l u eo ft h i sp a r a -
meter by LPS could be significantly attenuated by a pre-
or post-treatment with TAU (from 3.0 to 1.8, P<0.001
or from 3.0 to 2.4, P<0.01. respectively). The mean
inflammatory index of animals receiving only PBS (0.2)
probably reflects a transient inflammatory response
caused by the intratracheal instillation procedure itself.
Furthermore, TAU was found to prevent the inflamma-
tory response to LPS from spreading beyond the
parenchymal tissue and into the airways (Figure 15).
Discussion
Inflammation and oxidative stress are two closely related
events that contribute to ALI as a result of an exposure
to LPS. The inflammatory response that follows the
instillation of LPS into the lungs appears to develop
through an early and late phase process [38]. In the
early phase, there is an increase in BALF neutrophils,
albumin, free radical generation by the pulmonary
endothelium and neutrophils, upregulation of adhesion
molecules, and the release of cytokines and chemokines
for the massive recruitment of macrophages and
Figure 6 TAU attenuated the LPS-induced influx of total
leukocytes into BALF when given before or after LPS. Each bar
represents the mean ± S.E.M. for n = 6. ***P<0.001 vs. control;
++P<0.01 and
+++P<0.001 vs. LPS.
Figure 7 TAU attenuated the LPS-induced influx of neutrophils
into BALF when given before or after LPS. Each bar represents
the mean ± S.E.M. for n = 6. ***P<0.001 vs. control;
+P<0.05 vs. LPS.
Figure 8 TAU attenuated the LPS-induced influx of total
neutrophils into BALF when given before or after LPS. Each bar
represents the mean ± S.E.M. for n = 6. ***P<0.001 vs. control;
++P<0.01 and
+++P<0.001 vs. LPS.
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trophils in the air spaces of the lungs [14,39]. The late
phase, taking place 24-48 hr after LPS instillation, is
characterized by normalization of cytokine levels and
increases in the number of BALF neutrophils, mono-
cytes, macrophages and lymphocytes [38]. In the lung
epithelium, TNFR1 seems to facilitate the recruitment
of neutrophils after an exposure to LPS, in part by
enhancing chemokine secretion [39] and to participate
in a caspase-mediated signaling mechanism leading to
apoptotic cell death [40,41]. On the other hand, the acti-
vation of monocytes, macrophages and other cells is the
result of an interaction between LPS, bound to a LPS-
binding protein (LBP) in the circulation, and CD14/
TLR4 receptor complex on the target cells and culmi-
nates in the activation of transcription factors for cyto-
kine production and ROS generation [38,42]. The
upregulated release of ROS by phagocytic cells, along
with proinflammatory cytokines, proteolytic enzymes
and prostaglandins, eventually overwhelms the protec-
tive intracellular antioxidant mechanisms present in
lung tissue and induces a state of oxidative stress char-
acterized by the peroxidative degradation of membrane
phospholipids [9,11], the inactivation of antioxidant
enzymes [11,43], and the depletion of thiol-bearing
molecules such as proteins [44] and GSH [13,43].
Together, these alterations will contribute to lung tissue
injury manifested by epithelial permeability changes,
Figure 9 Photomicrographs showing cells in BALF samples after a staining with Wright’s solution. The animals received TAU (50 mg/kg/
0.5 mL, i.p.) before (A-C) and after (D-F) LPS (0.02 mg). Cells from control (PBS pH 7.4) animals exhibited a normal differential count, with the
majority of cells being macrophages (A and D). BALF from animals treated only with LPS (B and E) exhibited a higher number of neutrophils and
only a few macrophages relative to BALF from control (PBS pH 7.4) animals. A 3-day treatment with TAU, either before (C) or after (F) LPS,
reduced the number of neutrophils relative to BALF from animals receiving only LPS (magnification of 400x).
Figure 10 TAU attenuated the LPS-induced increase in TNFR1-
positive macrophages into BALF when given before or after
LPS. Each bar represents the mean ± S.E.M. for n = 6. ***P<0.001 vs.
control; ++P<0.01 vs. LPS.
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development of interstitial edema [9,39,45].
In the present investigation, the intratracheal instillation
of LPS into the lungs of Golden Syrian hamsters was suffi-
cient to induce an oxidative stress manifested by increased
formation of MDA, decreased GSH, and altered activities
of CAT, GPx and SOD. The reduction in GSH, the major
nonprotein sulfhydryl compound in the lung, may have
been caused by direct oxidation by ROS, by its increased
conversion to the oxidized (disulfide) form during the
removal of hydrogen peroxide and hydroperoxides by
GPx, or because of the inhibitory action of oxidants and
proinflammatory mediators on g-glutamylcysteine synthe-
tase (g-GCS), the key enzyme for GSH synthesis [14].
These alterations are in agreement with those reported
earlier by this and other laboratories for the prooxidant
action of LPS on the brain [46], heart [47], and lung
[13,24,48], and support the use of antioxidants as adjuncts
Figure 11 Photomicrographs of cells from BALF samples stained with Vectastain® Elite ABC kit. The animals received TAU (50 mg/kg/0.5
mL, i.p.) before (A-C) and after (D-F) LPS (0.02 mg). Cells from control (PBS pH 7.4) animals lacked TNFR1 positive cells (A and D). BALF from
animals treated only with LPS (B and E) exhibited a modest increase in the number of TNFR1 positive macrophages relative to BALF from
control (PBS pH 7.4) animals. A 3-day treatment with TAU, either before (C) or after (F) LPS, reduced the number of TNFR1 positive macrophages
relative to BALF from animals receiving only LPS (magnification of 400x).
Figure 12 TAU attenuated the LPS-induced increase in lung
TUNEL-positive apoptotic cells when given before or after LPS.
Each bar represents the mean ± S.E.M. for n = 6. ***P<0.001 vs.
control;
++P<0.01 and
+++P<0.001 vs. LPS.
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with conventional therapeutic agents.
Since a pretreatment with TAU reduced the formation
of MDA significantly and returned the GSH levels to
nearly control values confirm earlier results indicating
that this amino acid can attenuate LPO and preserve
the stores of GSH during periods of oxidative stress,
including chronic ethanol consumption [49], diabetes
mellitus [50,51], chemically-induced colitis [52] and iron
overload [53]. Since the protective effects of TAU were
greater when given as pretreatment than as a post-treat-
ment to LPS, it is possible that TAU could be negatively
influencing the formation of ROS by phagocytes and
surrounding lung cells [43,52]. Alternatively, TAU could
be preserving the intracellular GSH content by reducing
the deleterious effect of oxidants and proinflammatory
agents on redox-sensitive transcription factors regulating
the gene expression of g-GCS in the lungs [14].
Figure 13 Photomicrographs of lung sections stained with ApoTag® Plus Peroxidase In Situ Apoptosis Detection kit. The animals received TAU
(50 mg/kg/0.5 mL, i.p.) before (A-C) and after (D-F) LPS (0.02 mg). Sections from control (PBS pH 7.4) animals showed no TUNEL positive
apoptotic cells (A and D). Sections from animals treated only with LPS (B and E) showed a modest increase in the number of TUNEL positive
lung cells relative to samples from control (PBS pH 7.4) animals. A 3-day treatment with TAU, either before (C) or after (F) LPS, reduced the
number of TUNEL positive lung cells relative to samples from animals receiving only LPS (magnification of 400x).
Figure 14 TAU attenuated the LPS-induced lung increase in
inflammatory index when given before or after LPS. Each bar
represents the mean ± S.E.M. for n = 6. ***P<0.001 vs. control;
+++P<0.001 and
++P<0.01 vs. LPS.
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matic defenses available to the lung for the maintenance
of a normal antioxidant-oxidant balance. As previously
observed with BALF samples from the lung of hamsters
exposed to LPS, the activities of both CAT and SOD
were reduced and that of GPx increased [13]. Although
the same trend of results has been described earlier for
the liver of rodents acutely treated with LPS [16,54],
considerable variability seems to exist among labora-
tories regarding the effect of this endotoxin on the lung
activities of antioxidant enzymes. For example, it has
been reported that LPS reduced the activity of CAT,
GPx and SOD in the lung of mice inhaling a solution of
LPS in physiological saline for 5 days within an inhala-
tion chamber [11]; had no effect on the GPx activity
[55], and increased the CAT activity while decreasing
that of SOD activity [25] in the lung. Some of the fac-
tors underlining these discrepancies among antioxidant
enzyme activities during an inflammatory response to
LPS preceding ALI could be the animal species used in
the experiments [56,57] and factors related to the endo-
toxin itself such as the route of administration [56], the
dose administered [56], the duration of the exposure
[11], and the concentration of the solution used [56].
The higher than normal number of total leukocytes
and neutrophils found here for BALF samples from
hamsters instilled with LPS confirms the role of endo-
toxemia as a stimulus for the migration of neutrophils
into the lung in response to the in vivo production of
chemotatic factor by activated alveolar neutrophils and
macrophages [58]. The inhibitory action of TAU on
LPS-induced infiltration of the lung by leukocytes in
general and by neutrophils in particular appears to
occur subsequent to its conversion to TAU chloramine
(TAU-Cl) in activated neutrophils upon interaction with
hypochlorous acid (HClO) generated in the presence of
the myeloperoxidase (MPO)-halide system during the
phagocytosis of bacteria [30,59]. While TAU-Cl has
been reported to downregulate the production of
inflammatory mediators such as NO, prostaglandin E2
and tumor necrosis factora-( T N F - a) in activated
macrophages and neutrophils in an autocrine manner
[60], and to suppress superoxide anion and IL-6 and IL-
8 production in activated neutrophils [61,62], TAU itself
Figure 15 Photomicrographs of lung sections stained with H&E. (A-C) and (D-F) show the results for The animals received TAU (50 mg/kg/
0.5 mL, i.p.) before (A-C) and after (D-F) LPS (0.02 mg). Sections from control (PBS pH 7.4) animals showed no signs of inflammation in the
alveolar wall (A and D). Sections from animals treated only with LPS (B and E) showed a moderate inflammatory reaction and a mild thickening
of the alveolar wall. A 3-day treatment with TAU, either before (C) or after (F) LPS, reduced the inflammatory reaction in the alveolar wall and
thickening of the interstitium relative to lung sections from animals treated with LPS alone (magnification of 400x).
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Page 10 of 13was unable to suppress proinflammatory cytokine pro-
duction [63]. Similarly, although TAU and TAU-Cl can
both reduce the formation of products of the respiratory
burst by interferon-g (IFN-g)-stimulated peritoneal neu-
trophils, the effect of TAU-Cl is achieved at a much
lower dose that that required for TAU [61]. A similar
difference in effects between TAU and TAU-Cl has
been verified in vitro for eosinophils [64]. In addition to
its effect on the influx of both leukocytes and neutro-
phils into the lung airspaces, TAU was also found here
to attenuate the expression of TNFR1 on macrophages
present in BALF as a result of an exposure to LPS,
again to a greater extent when given before than after
LPS. These findings lend support the long held view
that TAU can serve as a potent inhibitor of inflamma-
tion and immune response in the lung [65,66], possibly
by modulating the transcriptionally regulated production
of proinflammatory and chemoattracting cytokines by
alveolar macrophages [59,62] and other activated leuko-
cytes [67,68] for the recruitment of blood monocytes
and neutrophils into the lung. In this context, TAU-Cl
appears to influence cytokine release by acting as a
negative effector on the signal pathway for the nuclear
translocation and activation of NF-Bf o rc y t o k i n e
synthesis by neutrophils, most likely by oxidizing Met45
residue of IBa [69]. An additional consequence of such
a modulatory effect by TAU-Cl, and of relevance to the
proinflammatory action of LPS in the lung, is the
decreased production of MCP-1 and MCP-2, two
chemokines that participate in the recruitment of
macrophages by activated neutrophils [59]. In addition,
TAU-Cl may be protecting the lungs by preventing the
transendothelial migration of neutrophils by shortening
their rolling velocity [70]; and by reducing lung arterial
pressure, hypoxia, MPO activity, and the excessive
release of inflammatory mediators and of products of
the respiratory burst activity by neutrophils [30].
As one of the major factors for ALI, LPS is found to
induce disseminated endothelial apoptosis prior to
endothelial tissue damage and that caspases play an
important role in the process [12]. While the protective
actions of TAU as TAU-Cl in the lung contrast sharply
with the known proapoptotic action associated with this
chlorinated TAU derivative on certain cells as a result
of direct damage to the mitochondrion [71], in the pre-
sent study TAU was found to reduce lung cell apoptosis.
Such a protection might have resulted from a decrease
in TNFR1 expression on lung cells, needed for stimula-
tion of the TNF-induced signaling pathway of apoptosis,
and from inhibition of a key caspase downstream in the
pathway, which was previously shown by this laboratory
to include caspase-3 [31].
Conclusions
The data reported here strongly suggest that TAU can
act in the lung as a protectant against the proinflamma-
tory, prooxidant and apoptotic actions of bacterial endo-
toxin, and that such a protection is achievable regardless
of whether TAU is administered before or after the
endotoxin. The magnitude of the protective actions of
TAU in the lung against endotoxin can be readily
assessed by monitoring the changes in BALF cell counts,
TNFR1 expression, the occurrence of alveolar apoptosis,
and in indices of oxidative stress; and. are in close
agreement with the results gathered by histopathological
examination of lung tissue samples.
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